Daraxonrasib Doubles Survival in Pancreatic Cancer Trial

For nearly half a century, metastatic pancreatic cancer has been the diagnosis oncologists dread giving and patients dread receiving. The disease killed Steve Jobs, Patrick Swayze, Alex Trebek, and Ruth Bader Ginsburg, and it claims roughly 50,000 American lives every year. Five-year survival hovers around 13 percent for all stages and drops to about 3 percent once the cancer has spread. Standard chemotherapy regimens such as gemcitabine and FOLFIRINOX have extended life by weeks, not years.

That grim arithmetic shifted this spring. Revolution Medicines, a clinical-stage biotech based in Redwood City, California, reported that its experimental oral drug daraxonrasib, also known as RMC-6236, nearly doubled overall survival in a pivotal Phase 3 trial of patients with previously treated metastatic pancreatic ductal adenocarcinoma. Researchers and patient advocates described the result as the most consequential pancreatic cancer data in a generation.

The Numbers Behind the Breakthrough

The study, called RASolute 302, was a global, randomized, controlled Phase 3 trial. Patients who received daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those given standard chemotherapy. The hazard ratio for death was 0.40, meaning the drug cut the risk of dying during the study by 60 percent. The result was statistically significant at p less than 0.0001.

Progression-free survival, the time before tumors started growing again, also improved meaningfully on the experimental arm. Daraxonrasib was taken as a 300 milligram pill once a day. Chemotherapy in the control arm was delivered intravenously, with the attendant side effects, infusion appointments, and hospital visits that have long defined the pancreatic cancer experience.

How the Drug Works

Daraxonrasib belongs to a new class of medicines called RAS multi-selective inhibitors. RAS is a family of genes that, when mutated, drives uncontrolled cell growth. Mutations in the KRAS gene specifically are found in more than 90 percent of pancreatic cancers, which is why RAS has been called the holy grail of cancer drug targets. For four decades it resisted every attempt to drug it.

Unlike earlier inhibitors that focused on a single mutation such as KRAS G12C, daraxonrasib binds to the active form of multiple RAS variants at once, including G12D, G12V, G12R, G13, and Q61, as well as wild-type RAS. That broad activity matters in pancreatic cancer, where G12D and G12V together account for the majority of tumors and where single-variant inhibitors have struggled to deliver durable benefit.

Doctors React to an Unprecedented Result

Brian Wolpin, director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute and a lead investigator on RASolute 302, summed up the response among oncologists. "A median survival of more than a year in the second-line setting really does get your attention," he said. Second-line pancreatic cancer is a setting in which most therapies have produced only marginal gains for decades.

Earlier Phase 1 and 2 data presented at the 2026 American Association for Cancer Research meeting added context. In a 40-patient cohort of first-line patients who received daraxonrasib combined with gemcitabine and nab-paclitaxel, the objective response rate reached 58 percent, with a disease control rate of 90 percent and six-month progression-free survival of 84 percent. Among treatment-naive patients on monotherapy, the response rate was 47 percent. Eileen O'Reilly of Memorial Sloan Kettering Cancer Center, who presented the monotherapy data, said the depth and duration of responses were unlike anything previously seen with a single agent in pancreatic cancer.

The safety profile, often a stumbling block for targeted cancer drugs, was reported as manageable. The company said the trial produced no new safety signals, and patients were generally able to stay on the oral therapy. That stands in sharp contrast to FOLFIRINOX, the most aggressive chemotherapy regimen for pancreatic cancer, which causes severe neuropathy, neutropenia, and fatigue and is often intolerable for older or frailer patients.

A Long Road From Lab Bench to Clinic

Revolution Medicines was founded in 2014 with a singular ambition: to drug the undruggable RAS pathway. The company spent years developing a chemistry platform that could lock RAS proteins into an inactive state. Daraxonrasib emerged as its lead candidate and the first RAS inhibitor designed to hit a broad spectrum of mutations simultaneously.

The Food and Drug Administration has already signaled urgency. The agency granted daraxonrasib Breakthrough Therapy Designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations, awarded the program a Commissioner's National Priority Voucher, and authorized an expanded access protocol so patients outside the trial can receive the drug while a full approval is pursued. The European Medicines Agency has issued a positive opinion on Orphan Drug Designation. Revolution Medicines has said it intends to file a New Drug Application based on the RASolute 302 data.

Two additional Phase 3 trials are underway. RASolute 303 is evaluating daraxonrasib in newly diagnosed metastatic patients, and RASolute 304 is testing it as an adjuvant therapy after surgery in patients whose tumors can still be removed. Positive readouts in either setting would dramatically expand the population eligible to benefit.

Wall Street and the Wider Pipeline

Investors responded quickly to the Phase 3 data. Shares of Revolution Medicines, traded on Nasdaq under the ticker RVMD, jumped sharply after the topline announcement and have continued to attract attention from healthcare investors and analysts who model peak sales for daraxonrasib in the multibillion-dollar range if approvals expand beyond pancreatic cancer. Royalty Pharma disclosed a financing arrangement tied to the program, underscoring how seriously the wider industry is taking the asset.

The implications reach beyond a single tumor type. RAS mutations are also common in colorectal and lung cancers, and Revolution Medicines is studying daraxonrasib in both settings as monotherapy and in combinations. A broadly active oral RAS inhibitor would represent one of the most significant additions to the oncology toolkit since the arrival of immune checkpoint inhibitors more than a decade ago.

What It Means for Patients

For families facing a pancreatic cancer diagnosis, the new data offer something that has been in short supply for generations: realistic hope. A median gain of more than six months is not a cure, and many patients will still die of their disease. But oncologists point out that doubling survival is the kind of step change that opens the door to combination strategies, earlier intervention, and eventually to longer-term remissions.

The Pancreatic Cancer Action Network, which has lobbied for decades for better treatments, called the RASolute 302 readout a watershed moment for the field. With expanded access already open in the United States and a regulatory submission expected, patients who once had little to look forward to beyond palliative chemotherapy may soon have a pill they can take at home, with the chance of months and possibly years they would not otherwise have seen.